Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Barry Honig involved in Xechem scam
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!!
https://www.sec.gov/news/press-release/2018-182
Honig involved in Xechem scam
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!!
https://www.sec.gov/news/press-release/2018-182
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped several stocks like Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!! IMO
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!!
https://www.sec.gov/news/press-release/2018-182
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!!
ALL IN MY OPINION
https://www.sec.gov/news/press-release/2018-182
Barry Honig, Michael Brauser, Konrad Ackermann, David Blech, Margy Chassman manipulated, pumped and dumped Xechem Pharmaceutical, shut it down and steal the assets, sold Patents and drugs like Nicosan, now Xickle, and drug candidates worth millions to their new private firm Invenux for $45k with Dr. Swift as marionette. Xickle, scd101 in Phase 1 trial, most promissing drug for Sickle Cell, 4 billion market. Shareholders were screwed!!!
BLECH,HONIG,BRAUSER, ACKERMANN ETC....ITS PRISON TIME
ALL IN MY OPINION
Florida investor Barry Honig, John Stetson, Michael Brauser, John R. O’Rourke III, Mark Groussman, Elliot Maza, Robert Ladd, Brian Keller, John H. Ford, Alpha Capital Anstalt, ATG Capital LLC, GRQ Consultants Inc., HS Contrarian Investments LLC, Grander Holdings Inc., Melechdavid Inc. and Stetson Capital Investments Inc. were also named in the SEC complaint.
https://kopitiambot.com/2018/09/09/billionaire-health-care-investor-phillip-frost-charged-by-sec-with-pump-and-dump-schemes/
He should be in prison a long time ago
Dr. Maza served as the Chairman of the Board of Directors and Chief Executive Officer of Intellect Neurosciences, Inc. since July 2014 until September 2017 and also serves as it's Chief Financial Officer from May 2006.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=8294489&privcapId=327199821
Our mission, for every European Antibody Congress, is to bring you the very best speakers from big pharma, biotechs, academia and technology innovators to discuss with you the most exciting breakthroughs when it comes to the discovery and development of antibodies. Whether that’s the newest format of a cancer killing ADC, the most advanced screening technology for mAbs, or the clinical development of a bispecific with promises to treat Alzheimer’s disease, we want to give you access to all of this to grow your knowledge, grow your business, and grow your connections.
https://www.terrapinn.com/template/Live/go/9834/0?&utm_source=terrapinn&utm_campaign=listing&utm_medium=link&utm_term=AF
A Long Journey into Aging, Brain Aging, and Alzheimer’s Disease Following the Oxidative Stress Tracks
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad170732
Role of oxidative stress in Alzheimer's disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840676/
https://seekingalpha.com/article/4167873-3-things-biotech-april-30-another-adc-another-breakthrough-another-immunotherapy
https://www.raredr.com/news/fda-grants-orphan-drug-designation-to-gastric-cancer-treatment-alt-p7
https://www.onclive.com/peer-exchange/breast-cancer-expanding-options/adcs-and-checkpoint-inhibitor-combinations-in-tnbc
PFE wanted ILNS patents, but Roche ABETA antibodies gantenerumab and crenezumab works - both could be empowered with conjumab (abeta or tau antibody + antioxdant like melatonin).... increase safety, higher dose, double mechanism, antiinflammatory....
Conjugation mab was a break through in cancer and is a multi billion market
No wonder if $200B Roche will come up with a deal.
MAZA terminated his IMNP agreement.
ALLIMO
It's all about efficacy and safety of higher-dose abeta antibodies
Conjumab-A
Elliot M. Maza resigned all positions held by him with Immune Pharmaceuticals Inc
https://marketexclusive.com/immune-pharmaceuticals-inc-nasdaqimnp-files-an-8-k-departure-of-directors-or-certain-officers-election-of-directors-appointment-of-certain-officers-compensatory-arrangements-of-certain-officer/2018/08/
Conjumab to improve abeta antibodies like crenezumab?
https://globenewswire.com/news-release/2018/07/25/1542308/0/en/New-Phase-2-Data-Analysis-for-Crenezumab-Presented-at-Global-Alzheimer-s-Conference-Provides-Strong-Evidence-for-Engagement-of-the-Principle-Abeta-Target.html
https://globenewswire.com/news-release/2013/02/13/523315/10021734/en/Intellect-Neurosciences-Issues-Letter-to-Shareholders.html
Could give significant value to ilns patents - abeta mab's works
https://www.alzforum.org/news/conference-coverage/four-immunotherapies-now-banish-amyloid-brain
Contact Chain for this
http://www.cerespir.com/contact/
https://taubiologic.com/
TauC3 antibody still in development!
History can tell a lot
Cytovia will go public, ....IPO, RTO?
ILNS will go through the roof in the next weeks
Look good for a RS!
Will buy a few more next week ;)
Maza hold 5% of ILNS
we will see it this month
Expect next move to $0.1
ILNS was cleaned up and is ready for a takeover, IMO
.....it's about the patents, IMO
Any thoughts about $ILNS?
Don't forget what they have in their backhand